Epilepsy: Early Infantile Epileptic Encephalopathy via the ARHGEF9 Gene
Summary and Pricing
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture ProbesTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
4095 | ARHGEF9 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Early Infantile Epileptic Encephalopathy (EIEE) is a clinically and genetically heterogeneous neurodevelopmental disorder. The key feature of EIEE is onset of frequent and/or severe seizures within the first few weeks of life (Noh et al., 2012. PubMed ID: 22342633).
ARHGEF9-related early infantile epileptic encephalopathy is a rare genetic cause for early infantile epilepsy with onset at birth or early infancy. The common symptoms of this disorder include delayed motor development, severe tonic and hyperekplectic seizures, hypertonia, intellectual disability and a particular facial dysmorphic feature. Brain MRI shows normal or brain atrophy, hypoplastic frontal lobe, hippocampal sclerosis, frontal polymicrogyria in the patients. Male patients have severe symptoms, whereas heterozygous females are unaffected (Shimojima et al., 2011. PubMed ID: 21633362). However, female cases with intellectual disability have been reported due to de novo large deletions or translocations or inversions that interrupt the ARHGEF9 gene and skewed X inactivation. Patients have variable responses to antiepileptic drugs (Alber et al., 2017. PubMed ID: 28589176; Shimojima et al., 2011. PubMed ID: 21633362; Marco et al., 2009. PubMed ID: 21731583).
Genetics
ARHGEF9-related early infantile epileptic encephalopathy is inherited in an X-linked recessive manner. It is caused by pathogenic variants in the ARHGEF9 gene encoding collybistin, a brain-specific GDP/GTP-exchange factor. Collybistin is required for both the initial formation and maintenance of gephyrin and gephyrin-dependent GABAA receptor clusters at inhibitory post-synapses in certain regions of the forebrain (Papadopoulos and Soykan, 2011. PubMed ID: 21738498).
Pathogenic variants in ARHGEF9 include missense, nonsense, splicing variants, large deletions and complex rearrangements involving the ARHGEF9 locus (Human Gene Mutation Database; Alber et al., 2017. PubMed ID: 28589176). De novo pathogenic variants in ARHGEF9 gene are common and include point variants, large deletions, translocations, and inversions (Alber et al., 2017. PubMed ID: 28589176).
Clinical Sensitivity - Sequencing with CNV PG-Select
In one study of males with severe intellectual disability (ID) and epilepsy of unknown cause, 4% (1 in 23) of cases were found to be caused by single nucleotide variations in ARHGEF9 (Shimojima et al., 2011. PubMed ID: 21633362). Another study of males and females with ID of unknown cause identified pathogenic ARHGEF9 variants in 4% of males (2 of 47) (de Ligt et al., 2012. PubMed ID: 23033978).
In a review of the phenotypic and genotypic spectrum of ARHGEF9 pathogenic variants, 7 out of 18 cases were found to be caused by large deletions, inversions, translocations or other complex arrangements involving ARHGEF9 (Alber et al., 2017. PubMed ID: 28589176).
Testing Strategy
This test provides full coverage of all coding exons of the ARHGEF9 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
The test is recommended for patients suspected to have ARHGEF9-related early infantile epileptic encephalopathy.
The test is recommended for patients suspected to have ARHGEF9-related early infantile epileptic encephalopathy.
Gene
Official Gene Symbol | OMIM ID |
---|---|
ARHGEF9 | 300429 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Epileptic Encephalopathy, Early Infantile, 8 | XL | 300607 |
Citations
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.